Secondary analysis of the PATH-HHT trial in hereditary haemorrhagic telangiectasia: higher baseline epistaxis severity and antifibrinolytic use were linked to better pomalidomide response at weeks 16–24; older age and ACVRL1 mutation to weaker response.
Secondary analysis
Al-Samkari et al. Characteristics associated with clinical response to pomalidomide in hereditary hemorrhagic telangiectasia